Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

Combinatorial Optimization of Chemotherapeutic Agents on T-Cell Acute Lymphoblastic Leukemia

Juhyung Kim, Hong Duc Nguyen Thi, Minh Tan Le, Hee Jeong Cho, Joon Ho Moon, Sang Kyun Sohn, Dong Won Baek

Blood (2023) 142 (Supplement 1): 5797.

https://doi.org/10.1182/blood-2023-188246

Published: 2023

Journal Articles

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Naval Daver, Kyoo Hyung Lee, Yunsuk Choi, Brian A. Jonas, Martha Arellano, Paul B. Koller, Chul W. Jung, Sang Kyun Sohn, Amir T. Fathi, Jeong-Ok Lee, Sung-Soo Yoon, Justin M. Watts, Pankit Vachhani, Ho-Jin Shin, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar

Blood (2023) 142 (Supplement 1): 162.

https://doi.org/10.1182/blood-2023-182296

Published: 2023

Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2023) 142 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2023-184431

Published: 2023

Journal Articles

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2023-180499

Published: 2023

Journal Articles

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Naval Daver, Kyoo Hyung Lee, Brian A. Jonas, Martha L. Arellano, Chul W. Jung, Sang Kyun Sohn, Sung-Soo Yoon, Jeong-Ok Lee, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6197–6199.

https://doi.org/10.1182/blood-2022-167972

Published: 2022

Journal Articles

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

Blood (2022) 140 (Supplement 1): 1018–1019.

https://doi.org/10.1182/blood-2022-166182

Published: 2022

Journal Articles

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Blood (2022) 140 (Supplement 1): 6592–6593.

https://doi.org/10.1182/blood-2022-171149

Published: 2022

Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park

Blood (2022) 140 (Supplement 1): 6850–6851.

https://doi.org/10.1182/blood-2022-168687

Published: 2022

Journal Articles

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Dong Won Baek, Sr., Joon Ho Moon, Jae-Sook Ahn, Seong Kyu Park, Ik Chan Song, Ho-Sup Lee, Won Sik Lee, Jong Ho Won, Hong Ghi Lee, June-Won Cheong, Yeung-Chul Mun, Chul W. Jung, Je-Hwan Lee, Hyeoung-Joon Kim, Sang Kyun Sohn

Blood (2021) 138 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2021-154470

Published: 2021

Journal Articles

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Blood (2021) 138 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2021-152008

Published: 2021

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Joon Ho Moon, MD, Hee Jeong Cho, MD, Dong Won Baek, MD, Sang Kyun Sohn, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Seunghyun Choi, PhD, Kyoung Ha Kim, MD PhD, Taehyung Kim, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4263.

https://doi.org/10.1182/blood-2019-130428

Published: 2019

Journal Articles

Clinical Impact of 18 f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

Dong Won Baek, MD, Hee Jeong Cho, Sang Kyun Sohn, MD PhD, Sung-Hoon Jung, MD, Hong chae Moon, Joon Ho Moon, MD

Blood (2019) 134 (Supplement_1): 3142.

https://doi.org/10.1182/blood-2019-129831

Published: 2019

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

Hawk Kim, MD PhD, Yunsuk Choi, MD, Sung-Soo Yoon, MD PhD, Soo-Mee Bang, MD PhD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Yong Park, MD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Ho Sup Lee, MD, Min Kyoung Kim, MD PhD, Won-Sik Lee, Jeong-Yeal Ahn, MD, Kyoo-Hyung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2018-99-116190

Published: 2018

Journal Articles

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MD PhD, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2018-99-112037

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Joon Ho Moon, MD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Yoojin Lee, MD PhD, Sang Kyun Sohn, MD PhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2018-99-116241

Published: 2018

Journal Articles

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MDPhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1391.

https://doi.org/10.1182/blood-2018-99-112906

Published: 2018

Journal Articles

Pilot Prospective Phase II Study of Nilotinib Combined with Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Acute Myeloid Leukemia with BCR/ABL1

Hawk Kim, MD PhD, Yunsuk Choi, MD, Sung-Soo Yoon, MD PhD, Won-Sik Lee, Jee Hyun Kong, MD, Kyoo-Hyung Lee, MD PhD, Jeong-Yeal Ahn, MD, Sang Kyun Sohn, MD PhD

Blood (2018) 132 (Supplement 1): 3020.

https://doi.org/10.1182/blood-2018-99-116488

Published: 2018

Journal Articles

Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse

TaeHyung Kim, Joon Ho Moon, Jae-Sook Ahn, Yeo-Kyeoung Kim, Seung-Shin Lee, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Seung Hyun Choi, Ja-yeon Lee, Marc S. Tyndel, Myung-Geun Shin, Yoo Jin Lee, Sang Kyun Sohn, Seong-Kyu Park, Zhaolei Zhang, Hyeoung-Joon Kim, Dennis Dong Hwan Kim

Blood (2018) 132 (15): 1604–1613.

https://doi.org/10.1182/blood-2018-04-848028

Published: 2018

Includes: Supplemental data

NARROW

Combinatorial Optimization of Chemotherapeutic Agents on T-Cell Acute Lymphoblastic Leukemia

Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Clinical Impact of 18 f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Pilot Prospective Phase II Study of Nilotinib Combined with Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Acute Myeloid Leukemia with BCR/ABL1

Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only